Lipigon Pharmaceuticals AB has announced that their drug candidate Lipisense has been given to humans for the first time. Lipisense is a drug candidate developed to lower blood lipid triglycerides in patients with severely elevated levels by preventing the production of the protein ANGPTL4 in the liver. The primary purpose of the phase I study is to document the candidate's safety, tolerability and pharmacokinetic profile while also evaluating efficacy on relevant biomarkers.

The preclinical studies of Lipisense were completed in 2021. Overall, they showed that Lipisense has a good safety profile. The drug candidate is now entering the clinical phase to be tested on humans.

Preliminary summary data are expected during the first half of 2023. The trial is a randomized, double-blind, placebo-controlled study of single ascending doses (SAD) and multiple ascending doses (MAD). The SAD part includes 20 healthy study participants, divided into four groups, and the primary goal is to evaluate safety and tolerability after an injection of Lipisense or placebo.

Four different dose levels of Lipisense will be tested to begin with.